Meropenem at recommended dose is a potential risk for seizure in hemodialysis patient

1Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Dosage adjustment of meropenem is usually recommended in hemodialysis (HD) patients and about 30% of meropenem is cleared during regular HD sessions. However, most of the published trials excluded patients on regular HD. Little is known about the accurate dosage of meropenem needed to avoid central nervous system toxicity. Herein, we report a 65-year-old Saudi female, a known case of end-stage renal disease on regular HD, who was admitted because of pyelonephritis and started on meropenem in the recommended dose according to cultures and sensitivity. She developed tonic-clonic convulsions after the 7thdose. Seizures were completely aborted after discontinuation of the offending drug. The recommended dosage of 500 mg daily in HD patients may still be too high particularly in Asian patients owing to their relatively small body mass index.

Cite

CITATION STYLE

APA

Al-Hwiesh, A., Alhwiesh, A., Abdul-Rahman, I., Al-Harbi, A., Mousa, D., Skiker, S., … Alqahtani, S. (2020). Meropenem at recommended dose is a potential risk for seizure in hemodialysis patient. Saudi Journal of Kidney Diseases and Transplantation, 31(6), 1427–1431. https://doi.org/10.4103/1319-2442.308364

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free